Revolution Medicines, Inc. Increase (Decrease) in Deposit Assets
Revolution Medicines, Inc. (RVMD) reported Increase (Decrease) in Deposit Assets of $18.31 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDepositOtherAssets · last filed 2026-08-05
- Revolution Medicines, Inc. increase (decrease) in deposit assets for the quarter ending 2026-06-30 was $7.75M, a 53.76% increase year-over-year.
- Revolution Medicines, Inc. increase (decrease) in deposit assets for the quarter ending 2026-03-31 was $10.56M.
- Revolution Medicines, Inc. increase (decrease) in deposit assets for the quarter ending 2025-12-31 was $7.30M, a 193.64% increase year-over-year.
- Revolution Medicines, Inc. increase (decrease) in deposit assets for the quarter ending 2025-09-30 was $251.00K.
- Revolution Medicines, Inc. increase (decrease) in deposit assets for fiscal 2025 was $12.02M, a 58.93% increase from fiscal 2024.
- Revolution Medicines, Inc. increase (decrease) in deposit assets for fiscal 2024 was $7.56M, a 231.13% increase from fiscal 2023.
- Revolution Medicines, Inc. increase (decrease) in deposit assets for fiscal 2023 was $2.28M.
| Period end | Increase (Decrease) in Deposit Assets 3 month | Increase (Decrease) in Deposit Assets 6 month | Increase (Decrease) in Deposit Assets 9 month | Increase (Decrease) in Deposit Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $18.31M 10-Q · filed 2026-08-05 | $25.60M derived: sum of 3 quarters · filed 2026-08-05 | $25.85M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $10.56M 10-Q · filed 2026-05-06 | $17.86M derived: sum of 2 quarters · filed 2026-05-06 | $18.11M derived: sum of 3 quarters · filed 2026-05-06 | $23.15M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $7.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $7.55M derived: sum of 2 quarters · filed 2026-02-25 | $12.59M derived: sum of 3 quarters · filed 2026-08-05 | $12.02M 10-K · filed 2026-02-25 |
| 2025-09-30 | $251.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $5.29M derived: sum of 2 quarters · filed 2026-08-05 | $4.72M 10-Q · filed 2025-11-05 | $7.21M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $5.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $4.47M 10-Q · filed 2026-08-05 | $6.96M derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-03-31 | -$565.00K 10-Q · filed 2026-05-06 | $1.92M derived: sum of 2 quarters · filed 2026-05-06 | ||
| 2024-12-31 | $2.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $7.56M 10-K · filed 2026-02-25 | ||
| 2024-09-30 | $5.08M 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $2.28M 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |